

The conformable foam dressing with exudate channels

- Enhanced exudate management¹
- Effectively manages even high viscous exudate²
- Non-traumatic to the wound and surrounding skin on removal^{3,4}
- Minimises pain at dressing changes³⁻⁵

Safetac® layer


- Reduces pain and trauma at dressing change³⁻⁵
- Does not adhere to the moist wound bed but to dry skin only
- Seals the wound margins and reduces risk of maceration⁶

Polyurethane backing film

- Breathable
- Barrier to virus and bacteria > 25nm⁷

Polyurethane foam pad


- Enhanced exudate management capacity¹
- Exudate channels to absorb viscous exudate²
- Conformable and flexible foam⁸



Safetac® technology. Less trauma. Less pain.

Safetac is a patented technology. Dressings with Safetac technology are atraumatic upon removal.³ These dressings minimise trauma to the wound and the surrounding skin, which minimises pain to the patient.³⁻⁵ The risk of maceration is minimised by sealing the wound margins.⁶

For more information visit www.molnlycke.co.uk/solutions/safetac-technology




Skin stripping occurs with traditional adhesive



No skin stripping occurs with Safetac technology


How to use Mepilex® XT



1. Cleanse the wound in accordance with normal procedures. Dry the surrounding skin thoroughly. Remove the release films.



2. For best results, Mepilex XT should overlap the dry surrounding skin by at least 1-2 cm for the smaller sizes (sizes up to 10 x 11 cm) and 5 cm for the larger sizes in order to protect the surrounding skin from maceration and excoriation and fixate the dressing securely. If required, Mepilex XT can be cut to various wound shapes. Do not stretch.



3. When necessary, secure Mepilex XT with a bandage or other fixation.

How Mepilex XT works

Mepilex XT is a soft and conformable⁸ foam dressing with integrated channels, designed to transfer exudate rapidly² into the absorbent foam pad.

Safetac technology seals the wound edges, preventing exudate from leaking onto the surrounding skin, thus minimising the risk of maceration.⁶ Safetac also ensures that the dressing can be changed with minimised risk of damaging the wound or surrounding skin or exposing the patient to additional pain.³⁻⁵

Benefits of Mepilex XT

- Minimises maceration, absorbs both low to high viscose exudate^{2,5,6}
- Can be used in all exuding wound healing stages
- Minimises pain and trauma at dressing changes³⁻⁵
- Promotes patient comfort⁸
- Well suited for use under compression bandages²
- Can remain in place for several days depending on the condition of the wound^{2,8,9}
- Can be cut to suit various wound shapes and difficult-to-dress locations
- Stays in place allowing for "hands-free" application of compression or retention bandages^{2,9}
- Can be lifted and adjusted without losing its adherent properties
- Non-sensitising^{2,10}

Areas of use

Mepilex XT is designed for a wide range of low to moderate exuding acute and chronic wounds in all healing phases, such as leg and foot ulcers, pressure ulcers and traumatic wounds.

Note

- Do not use on patients with known sensitivity to the dressing or its components.
- In case of signs of clinical infection, consult a health care professional for adequate infection treatment.
- Do not use Mepilex XT together with oxidising agents such as hypochlorite solutions or hydrogen peroxide.
- Mepilex XT can be used under compression and does not need to be cut to the size of the wound.



Mepilex Family Ordering information (sterile packed)

Product	Art. no	Size cm	Pieces per inner	NHSSC Code	PIP Code
Mepilex	294015	5 x 5	5	ELA715	377-5939
Mepilex XT	211160	10 x 11	5	ELA722	395-3320
Mepilex XT	211260	11 x 20	5	ELA723	395-3338
Mepilex XT	211360	15 x 16	5	ELA724	395-3346
Mepilex XT	211460	20 x 21	5	ELA725	395-3353
Mepilex	294500	20 x 50	2	ELA383	342-9537

Mepilex XT is available at the same cost effective price as Mepilex.

References:

1. Fluid handling and retention properties Mepilex XT: Report no. 20130123-006/20121107-014/20130729-001 (SMTL). 2. Fluid handling and retention properties with Viscous test Fluid Mepilex XT, Report No. 20130104-004/ 20121012-004/20130515-001/20130814-004(MHC). 3. White R. A Multinational survey of the assessment of pain when removing dressings. Wounds UK, 2008 4. Meuleneire F and Fostier A. Local treatment of heel pressure ulcers with a silicone foam dressing. Poster presentation. WUWHS, 2008. 5. Upton D and Solowiej K. The impact of atraumatic vs conventional dressings on pain and stress. J Wound Care. 2012 May; 21(5):209-215. 6. Wiberg A.B. et al. Preventing maceration with a soft silicone dressing: in-vitro evaluations. Poster presented at the 3rd Congress of the WUWHS, Toronto, Canada, 2008. 7. External Test Lab Report no. 413098 (Nelson Laboratories). 8. Meuleneire F and Fostier A. Local treatment of heel pressure ulcers with a silicone foam dressing. Poster presentation. WU WHS, 2008. 9. Eager CA. Comparison of two foams through the measurement of healing time, frequency of dressing changes and peri wound status. Poster presentation. Advanced Wound Care and Medical Research Forum on Wound Repair, 2001. 10. Biocompatibility Evaluation, Filed in MHC. 11. Based on Drug Tariff prices March 2015.

www.molnlycke.co.uk

Mölnlycke Health Care Ltd, Arenson Centre, Arenson Way, Dunstable, Bedfordshire LU5 5UL, UK. Tel. +44 (0) 870 6060766.
The Mölnlycke Health Care name and logo, Mepilex® XT and Safetac® are registered trademarks of Mölnlycke Health Care AB.
©2015 Mölnlycke Health Care. All rights reserved.

